Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

74
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
74
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

54
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
54
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

17
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
17
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

42.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2020
Same author

Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia.

European journal of gastroenterology & hepatology·2020
Same author

Genetically Engineered Mouse Models for Liver Cancer.

Cancers·2019
Same author

Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study.

Korean journal of radiology·2019
Same author

Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.

Hepatology international·2019
Same author

Comparison of Renal Function Estimation Formulae for Dosing Direct Oral Anticoagulants in Patients with Atrial Fibrillation.

Journal of clinical medicine·2019

Related Experiment Video

Updated: Apr 23, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Emerging therapies for hepatitis C.

Do Young Kim1, Sang Hoon Ahn1, Kwang-Hyub Han1

  • 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Gut and Liver
|September 18, 2014
PubMed
Summary
This summary is machine-generated.

Direct-acting antivirals (DAAs) offer new hope for treating hepatitis C virus (HCV) infections. These drugs, targeting viral replication, provide shorter treatment durations and fewer adverse events than older therapies.

Keywords:
Direct acting antiviralHepatitis CPegylated interferonRibavirin

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.9K

Related Experiment Videos

Last Updated: Apr 23, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.9K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Pegylated interferon (PEG-IFN) and ribavirin (RBV) are current therapies for hepatitis C virus (HCV).
  • Direct-acting antivirals (DAAs) target HCV nonstructural proteins to inhibit viral replication.
  • First-generation NS3/4A protease inhibitors like boceprevir and telaprevir showed improved efficacy for genotype 1 HCV.

Purpose of the Study:

  • To review the development and efficacy of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection.
  • To highlight the advancements in HCV treatment beyond traditional interferon-based therapies.
  • To discuss the role of different DAA classes in HCV management.

Main Methods:

  • Review of clinical trial data and published literature on DAAs for HCV.
  • Analysis of the efficacy and safety profiles of various DAA agents.
  • Comparison of DAA-based regimens with standard PEG-IFN/RBV therapy.

Main Results:

  • First-generation NS3/4A protease inhibitors (boceprevir, telaprevir) improved outcomes for genotype 1 HCV.
  • Second-wave NS3/4A inhibitors (simeprevir, faldaprevir, asunaprevir) are emerging.
  • Daclatasvir (NS5A inhibitor) and sofosbuvir (NS5B inhibitor) offer high potency and are crucial for combination therapy across genotypes.
  • Sofosbuvir-based regimens can achieve interferon-free treatment, reducing duration and improving tolerability.

Conclusions:

  • DAAs represent a significant advancement in HCV treatment, offering high cure rates.
  • Combination DAA therapy allows for shorter treatment durations and improved patient outcomes.
  • DAAs provide a new paradigm for managing HCV infections with better safety and efficacy profiles.